Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085363 | 0.91 | TBXA2R (0.39) | ALDH1A1PTGER2PTGER4PTGER3PDE4D | |
| SCHEMBL6092808 | 0.88 | — | — | |
| SCHEMBL6085993 | 0.87 | PTGS1 (0.35) | KDM4EPTGER4PTGER3TBXA2RPTGDR | |
| SCHEMBL6086678 | 0.86 | ALDH1A1 (0.40) | ALDH1A1KDM4EHKDC1TDP1SAE1 | |
| SCHEMBL7099597 | 0.84 | KDM4E (0.44) | ALDH1A1KDM4EHKDC1TDP1SAE1 | |
| SCHEMBL6085069 | 0.77 | TBXA2R (0.39) | ALDH1A1PTGER2EPHX2PTGER4PTGER3 | |
| SCHEMBL15385466 | 0.75 | ALOX5 (0.44) | ALDH1A1TDP1EPHX2PDE4DLMNA | |
| SCHEMBL8903251 | 0.74 | PDE4D (0.51) | ALDH1A1KDM4EHKDC1TDP1SAE1 | |
| SCHEMBL8901601 | 0.74 | PDE4D (0.51) | ALDH1A1KDM4EHKDC1TDP1SAE1 | |
| SCHEMBL8901597 | 0.74 | PDE4D (0.51) | ALDH1A1KDM4EHKDC1TDP1SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019149-B2 | Thromboxane ligands without blood clotting side effects | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-5516791-A | VISION DEFECTS FOR TREATMENT OF HYPERTENSION OF EYES | ALLERGAN (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, OXTR | ALDH1A1 1904/4885KDM4E 4042/4885HKDC1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.